NCT06788002

LDRT and Chemoimmunotherapy in NPC With Liver Metastasis

Low-dose Radiotherapy and Chemoimmunotherapy in Nasopharyngeal Carcinoma With Liver Metastasis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 26 (estimated)
• Sponsor: Hunan Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the efficacy and toxicity of adding low-dose radiotherapy to chemoimmunotherapy as a first-line treatment for nasopharyngeal carcinoma patients with liver metastasis.

Detailed description

Low-dose radiotherapy to the liver metastasis. Chemotherapy: gemcitabine and cisplatin Immunotherapy: penpulimab

Conditions

• Nasopharyngeal Cancinoma (NPC)

Interventions

Type	Name	Description
OTHER	Low-dose radiotherapy combine with chemoimmunotherapy	Radiation: 1.4Gy for 5 days to the liver metastasis before chemoimmunotherapy. Chemoimmunotherapy: gemcitabine(1000mg per square meter on days 1,8) , cisplatin (80mg per square meter on day 1), penpulimab (200mg, day1)

Timeline

• Start date: 2025-01-14
• Primary completion: 2026-06-30
• Completion: 2027-06-30
• First posted: 2025-01-22
• Last updated: 2026-04-02

Locations

7 sites across 1 country: China